Urinary excretion of liver-type fatty acid-binding protein reflects the severity of sepsis

被引:0
|
作者
Sato E. [1 ]
Kamijo-Ikemori A. [2 ,4 ]
Oikawa T. [3 ]
Okuda A. [3 ]
Sugaya T. [3 ,4 ]
Kimura K. [5 ]
Nakamura T. [1 ,4 ]
Shibagaki Y. [4 ]
机构
[1] Division of Nephrology, Department of Medicine, Shinmatsudo Central General Hospital, 1-380 Shinmatsudo, Matsudo,Chiba
[2] Department of Anatomy, St. Marianna University School of Medicine, Sugao, Miyamae-Ku, Kawasaki,Kanagawa
[3] Cmic Holdings Co. Ltd., Hamamatsucho Bldg., 1-1-1 Shibaura, Minato-ku, Tokyo
[4] Department of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Sugao, Miyamae-Ku, Kawasaki, 216-8511, Kanagawa
[5] Department of Internal Medicine, Japan Community Health Care Organization, Tokyo Takanawa Hospital, Tokyo
关键词
AKI; Biomarker; L-FABP; Oxidative stress; POC; Sepsis;
D O I
10.1186/s41100-017-0107-x
中图分类号
学科分类号
摘要
Sepsis due to microbial invasion often causes multiple organ failure (MOF), including acute kidney injury (AKI), with high mortality rates in serious cases. Hence, there is an urgent need for diagnostic biomarkers that can be used to rapidly, accurately, and easily detect sepsis to identify the condition early and guide the selection of appropriate treatment. Liver-type fatty acid-binding protein (L-FABP), which localizes in renal proximal tubules, is excreted into the urine in response to oxidative stress-induced tubular injury. Because of this mechanism, L-FABP has been reported to be a useful urinary biomarker not only for renal disease but also for the severity of sepsis. Based on this concept, we developed a new L-FABP point-of-care (POC) assay kit that can be used to rapidly measure human L-FABP in the urine to further improve the usefulness of this biomarker in clinical settings. In this review, we describe the molecular mechanisms of L-FABP, its clinical usefulness, and the performance of the POC assay kit. © 2017 The Author(s).
引用
收藏
相关论文
共 50 条
  • [41] The Role of Elevated Liver-Type Fatty Acid-Binding Proteins in Liver Diseases
    Eguchi, Akiko
    Iwasa, Motoh
    PHARMACEUTICAL RESEARCH, 2021, 38 (01) : 89 - 95
  • [42] The Role of Elevated Liver-Type Fatty Acid-Binding Proteins in Liver Diseases
    Akiko Eguchi
    Motoh Iwasa
    Pharmaceutical Research, 2021, 38 : 89 - 95
  • [43] Urinary liver-type fatty acid-binding protein is independently associated with graft failure in outpatient kidney transplant recipients
    Yepes-Calderon, Manuela
    Sotomayor, Camilo G.
    Pena, Michelle
    Eisenga, Michele F.
    Gans, Rijk O. B.
    Berger, Stefan P.
    Moers, Cyril
    Sugaya, Takeshi
    Doekharan, Dew
    Navis, Gerjan J.
    van den Born, Jaap
    Bakker, Stephan J. L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 (04) : 1535 - 1544
  • [44] Urinary Liver-Type Fatty Acid-Binding Protein Predicts Residual Renal Function Decline in Patients on Peritoneal Dialysis
    Torigoe, Kenta
    Muta, Kumiko
    Tsuji, Kiyokazu
    Yamashita, Ayuko
    Ota, Yuki
    Kitamura, Mineaki
    Mukae, Hiroshi
    Nishino, Tomoya
    MEDICAL SCIENCE MONITOR, 2020, 26
  • [45] URINARY LIVER-TYPE FATTY ACID-BINDING PROTEIN IS ASSOCIATED WITH AORTIC STIFFNESS IN MALE CORONARY ARTERY DISEASE PATIENTS
    Paapstel, K.
    Zilmer, M.
    Eha, J.
    Tootsi, K.
    Piir, A.
    Kals, J.
    ATHEROSCLEROSIS, 2016, 252 : E63 - E63
  • [46] Cigarette smoking affects urinary liver-type fatty acid-binding protein concentration in patients with early diabetic nephropathy
    Nakamura, Tsukasa
    Sugaya, Takeshi
    Koide, Hikaru
    DIABETES CARE, 2006, 29 (07) : 1717 - 1717
  • [47] Urinary excretion of liver fatty acid-binding protein in health-check participants
    Ishimitsu T.
    Ohta S.
    Saito M.
    Teranishi M.
    Inada H.
    Yoshii M.
    Minami J.
    Ono H.
    Hikawa A.
    Shibata N.
    Sugaya T.
    Kamijo A.
    Kimura K.
    Ohrui M.
    Matsuoka H.
    Clinical and Experimental Nephrology, 2005, 9 (1) : 34 - 39
  • [48] Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner
    Kitada, Munehiro
    Tsuda, Shin-ichi
    Konishi, Kazunori
    Takeda-Watanabe, Ai
    Fujii, Mizue
    Kanasaki, Keizo
    Nishizawa, Makoto
    Nakagawa, Atsushi
    Koya, Daisuke
    BMJ OPEN DIABETES RESEARCH & CARE, 2017, 5 (01)
  • [49] The Urinary Level of Liver-type Fatty Acid Binding Protein in Children with Febrile UTI
    Rafiei, Alireza
    Arzefuni, Fatemeh Abedi
    Mohammadjafari, Hamid
    Yazdani-Charati, Jamshid
    IRANIAN JOURNAL OF KIDNEY DISEASES, 2020, 14 (03) : 191 - 197
  • [50] Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenic mice
    Kamijo-Ikemori, Atsuko
    Sugaya, Takeshi
    Sekizuka, Ayako
    Hirata, Kazuaki
    Kimura, Kenjiro
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (03) : 788 - 800